These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 30293943)
1. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Asao T; Takahashi F; Takahashi K Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943 [TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age. Ke L; Xu M; Jiang X; Sun X Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372 [TBL] [Abstract][Full Text] [Related]
3. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
4. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. Tan AC; Itchins M; Khasraw M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103 [TBL] [Abstract][Full Text] [Related]
5. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation]. Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279 [TBL] [Abstract][Full Text] [Related]
6. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion. Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926 [TBL] [Abstract][Full Text] [Related]
7. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792 [TBL] [Abstract][Full Text] [Related]
9. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Gainor JF; Shaw AT Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043 [TBL] [Abstract][Full Text] [Related]
10. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228 [TBL] [Abstract][Full Text] [Related]
11. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241 [TBL] [Abstract][Full Text] [Related]
12. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau]. Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155 [No Abstract] [Full Text] [Related]
14. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728 [TBL] [Abstract][Full Text] [Related]
15. [Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer]. Pan S; Wang N; Song X Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):615-621. PubMed ID: 36002199 [TBL] [Abstract][Full Text] [Related]
16. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. Chen LF; Chen XY; Yu XB Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383 [TBL] [Abstract][Full Text] [Related]
17. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases. Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341 [TBL] [Abstract][Full Text] [Related]
18. Correlation between combining Ruan M; Liu L; Wang L; Lei B; Sun X; Chang C; Shen Y; Xie W Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590 [TBL] [Abstract][Full Text] [Related]
19. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Rosell R; Karachaliou N; Wolf J; Ou SH Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349 [No Abstract] [Full Text] [Related]
20. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. Brisudova A; Skarda J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]